Is there a place for intra-articular corticosteroid injections in the treatment of knee osteoarthritis?
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.l6923 (Published 15 January 2020) Cite this as: BMJ 2020;368:l6923
- John W Orchard, adjunct professor
- School of Public Health, University of Sydney, New South Wales 2006, Australia
- john.orchard{at}sydney.edu.au
What you need to know
Intra-articular corticosteroid injections possibly improve pain and function in the short term (<8 weeks) in patients with osteoarthritis of the knee, but the evidence is of low quality, and any benefit is not usually sustained beyond 3 months
Emerging evidence suggests a possible small risk of joint deterioration and worsening symptoms over the long term with intraarticular corticosteroid injections
Consider the severity of pain, feasibility of other treatment options including exercise, and the patient’s preferences regarding risks and benefits when planning treatment
The prevalence of end-stage knee osteoarthritis requiring joint replacement is increasing globally.1 Some of this increase is due to increasing obesity and worsening lifestyle factors such as poor physical activity. It also requires us to evaluate whether standard treatments for mild to moderate osteoarthritis are effective.
Intra-articular corticosteroid, also referred to as corticosteroid injection, is widely prescribed for osteoarthritis of the knee. Guidelines, such as those produced by the National Institute for Health and Care Excellence (NICE),2 have traditionally supported its use,3 but reviews of efficacy indicate a high degree of uncertainty.45 On average, a patient might have symptomatic knee osteoarthritis for 30 years. It is uncertain how the long term safety or harms of corticosteroid injection balance against the likelihood of short term pain improvement.
What is the evidence of uncertainty?
Systematic reviews indicate low quality evidence that intra-articular corticosteroid injections may provide short term pain relief and a small improvement in physical function for up to six weeks in knee osteoarthritis compared with placebo.46 Patients with more severe disease are likely to experience greater improvement.7 The benefits are not seen to last beyond three months in trials,4 although individual patients may report longer periods of symptom relief. There is considerable heterogeneity between trials. While corticosteroid injections have been found to be safe in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.